에스티팜

237690KOSDAQ

49.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

ESTEPAF, originally established as Samcheonri Pharmaceutical in 1983 and later acquired by Dong-A Ssosiogroup in 2010, has expanded into the oligonucleotide CDMO sector, achieving global top 3 production capacity. It entered the mRNA business in 2020, completed the second oligo facility in 2025, and is advancing clinical trials for its self-developed drugs STP0404 (HIV treatment) and STP1002 (cancer treatment). The company has integrated CRO and CDMO services into a one-stop system, enhancing its pharmaceutical development capabilities through global partnerships.

Number of Employees

1,560people

Average Salary

68.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

33.19Industry Average 15.000.0Point

2.2x industry avg (risky)

PBR

3.16Industry Average 1.200.0Point

2.6x industry avg (risky)

ROE

9.96Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

4.18Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 7.4% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 89,800Won52-week high 168,70052-week low 82,400

1-month return3.0Point

1m -0.11% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral기업설명회(IR)개최2026-10-22
Neutral결산실적공시예고2026-10-22
Neutral주식등의대량보유상황보고서(일반)2026-10-08
Neutral투자판단관련주요경영사항(임상시험결과) (HIV-1 치료제 STP0404 임상 2a상 임상시험결과보고서(CSR) 수령)2026-10-06
Neutral주식등의대량보유상황보고서(약식)2026-10-02